Abstract
Atrial fibrillation (AF) is the most common heart rhythm disorder, with increasing prevalence in the aging population. The clinical presentation and evolution of AF can be highly variable. Therefore, treatment of AF can be challenging in some patients. This review summarizes recent developments in both prevention of thromboembolic events and rate/rhythm control highlighting the possibilities of behavioral, pharmacological, and catheter-based perspectives.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Anti-Arrhythmia Agents / administration & dosage
-
Anti-Arrhythmia Agents / therapeutic use
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy
-
Atrial Fibrillation / epidemiology
-
Atrial Fibrillation / prevention & control
-
Atrial Fibrillation / therapy*
-
Calcium Channel Blockers / administration & dosage
-
Calcium Channel Blockers / therapeutic use
-
Catheter Ablation*
-
Digitalis Glycosides / administration & dosage
-
Digitalis Glycosides / therapeutic use
-
Drug Therapy, Combination
-
Electric Countershock*
-
Heparin / administration & dosage
-
Heparin / therapeutic use
-
Humans
-
Life Style
-
Male
-
Middle Aged
-
Patient Selection
-
Quality of Life
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Secondary Prevention
Substances
-
Anti-Arrhythmia Agents
-
Anticoagulants
-
Calcium Channel Blockers
-
Digitalis Glycosides
-
Heparin